Vertex Pharmaceuticals Incorporated (VRTX) Shares Bought by Stifel Financial Corp

Stifel Financial Corp grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 17.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,901 shares of the pharmaceutical company’s stock after purchasing an additional 9,685 shares during the period. Stifel Financial Corp’s holdings in Vertex Pharmaceuticals were worth $9,864,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Vertex Pharmaceuticals by 15.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after acquiring an additional 132 shares during the period. FNY Partners Fund LP lifted its holdings in shares of Vertex Pharmaceuticals by 900.0% during the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after acquiring an additional 900 shares during the period. Smithfield Trust Co. bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $135,000. FNY Managed Accounts LLC bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $162,000. Finally, Dupont Capital Management Corp bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth about $186,000. 93.33% of the stock is owned by institutional investors.

A number of research firms have recently commented on VRTX. BMO Capital Markets reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. Robert W. Baird reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Needham & Company LLC reissued a “buy” rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Sunday, September 17th. Cowen reissued a “buy” rating and set a $200.00 price target on shares of Vertex Pharmaceuticals in a report on Monday. Finally, Vetr downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price target for the company. in a report on Monday, September 4th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have assigned a buy rating to the company’s stock. Vertex Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $173.15.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $141.68 on Tuesday. Vertex Pharmaceuticals Incorporated has a 1 year low of $71.46 and a 1 year high of $167.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14. The firm has a market cap of $36,319.37, a PE ratio of 239.35, a price-to-earnings-growth ratio of 3.44 and a beta of 1.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company had revenue of $578.20 million during the quarter, compared to analysts’ expectations of $522.07 million. During the same quarter in the previous year, the company earned $0.16 EPS. Vertex Pharmaceuticals’s revenue was up 39.7% on a year-over-year basis. equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.76 earnings per share for the current fiscal year.

In other news, CMO Jeffrey Chodakewitz sold 3,437 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $151.64, for a total transaction of $521,186.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Amit Sachdev sold 40,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $145.05, for a total transaction of $5,802,000.00. Following the sale, the executive vice president now owns 89,810 shares of the company’s stock, valued at approximately $13,026,940.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 343,519 shares of company stock valued at $49,488,660. 1.80% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Shares Bought by Stifel Financial Corp” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/12/vertex-pharmaceuticals-incorporated-vrtx-shares-bought-by-stifel-financial-corp.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

What are top analysts saying about Vertex Pharmaceuticals Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vertex Pharmaceuticals Incorporated and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit